DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing

Information source: Medtronic Cardiac Rhythm Disease Management
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Left Ventricular Dysfunction

Intervention: RV lead placement site (Other)

Phase: N/A

Status: Recruiting

Sponsored by: Medtronic Cardiac Rhythm Disease Management

Official(s) and/or principal investigator(s):
Dr. Gerald Kaye, Study Chair, Affiliation: Princess Alexandra Hospital

Overall contact:
Natalie Middleton Middleton, Email: natalie.middleton@medtronic.com

Summary

This study will be done in patients who require the implantation of a cardiac pacemaker (an electronic device that controls the heartbeat) for complete heart block (a heart rhythm abnormality resulting in a slow heart beat). Pacemakers regulate the heart beat by delivering pulses of electricity through special wires (pacing leads) which are placed inside the heart.

This study will compare two groups of pacemaker patients. Each group will have their pacing leads placed in a particular location in the heart. The purpose of the study is to show whether the position used in one group is better for maintaining effective heart function compared to the position used in the other group.

The leads in one group will be placed in a position called the Right Ventricular Apex. This is the traditional and most frequently used position for pacemaker leads.

The leads in the other group will be placed in a position called the Right Ventricular High Septum. This is a less commonly used position, but may result in health benefits for the patients compared with the Right Ventricular Apex.

Clinical Details

Official title: PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing. Does Right Ventricular High-Septal Pacing Improve Outcome Compared With Right Ventricular Apical Pacing?

Study design: Treatment, Randomized, Single Blind (Subject), Active Control, Parallel Assignment, Efficacy Study

Primary outcome: Comparison of change in Left Ventricular Ejection Fraction between the two patient groups.

Secondary outcome:

Incidence of atrial tachyarrhythmia recorded by the pacemakers

Worsening of heart failure

All cause mortality

Incidence of stroke

N-Terminal Brain Natriuretic Peptide (NT-proBNP) levels

Echocardiographic measures of left ventricular dyssynchrony

6 minute Hall-Walk distance

Detailed description: There is an increasing amount of evidence to suggest that other positions in the heart may be more effective than the conventional Right Ventricular Apex (RVA) position for restoring good heart function. The best site to place a lead has not yet been proven.

This is a study comparing the long term clinical effects of two different lead positions. The measurements taken to assess the clinical effects include:

- the effectiveness of the heart's pumping action (as measured by ultrasound scans)

- measurements of how far patients can walk in 6 minutes

- analysis of blood samples

- collection of information from the pacemaker about heart rhythm problems

Half of the patients in the study will receive conventional leads placed in the more common RVA position in the heart. The other half will receive a relatively new type of lead placed in what is called the Right Ventricular High Septal (RVHS) position.

In order to fairly compare the outcomes of these two different lead positions this study has been designed as a 'randomized', 'blind' trial. This means that the group which patients will be entered into will be chosen at random and patients will not be told which group they are in.

Patients will each have an equal (50: 50) chance of being in either group. By carefully comparing the clinical differences between the two groups of patients, the study aims to prove whether or not there are additional benefits for patients when the RVHS lead position is used.

All leads used in the study have been shown to be safe for patients and are available commercially for implantation. All of the implanting doctors involved in the study are experienced at implanting the pacemakers and leads that will be used in this study.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with high grade AV block and sinus rhythm, scheduled to undergo dual chamber

pacemaker implantation OR patients with high grade AV block and permanent atrial fibrillation, scheduled to undergo single chamber ventricular pacemaker implantation.

- Patients aged 18 years or older.

Exclusion Criteria:

- Patients indicated for an Implantable Cardioverter Defibrillator or Cardiac

Resynchronization Therapy.

- Patients following junctional ablation.

- Patients with a Myocardial Infarction within three months prior to enrollment.

- Patients that received bypass surgery within three months prior to enrollment.

- Patients that had a valve replacement within three months prior to enrollment or

patients with a mechanical right heart valve.

- Patients where a right ventricular lead cannot be placed i. e. complex congenital

heart disease.

- Patients with hypertrophic obstructive cardiomyopathy.

- Patients with acute coronary syndrome, unstable angina, severe mitral regurgitation

and/or hemodynamically significant aortic stenosis.

- Previous implanted pacemaker or cardioverter defibrillator.

- Known paroxysmal atrial fibrillation or a documented episode of atrial fibrillation

prior to enrollment.

- Patients on amiodarone therapy within the last six months prior to enrollment.

- Terminal conditions with a life expectancy of less than two years.

- Participation in any other study that would confound the results of this study.

- Psychological or emotional problems that may interfere with the volunteer's ability

to provide full consent or fully understand the purposes of the study.

- Pregnant patients or patients who may become pregnant during the time-scale of the

study.

Locations and Contacts

Natalie Middleton Middleton, Email: natalie.middleton@medtronic.com

Auckland City Hospital, Auckland, New Zealand; Recruiting
Kelly Reynish, Phone: +64 9 630 9923
Nigel Lever, Principal Investigator

Christchurch Hospital, Christchurch, New Zealand; Recruiting
Bronwyn Davies, Phone: +64 3 3641096
Ian Crozier, Principal Investigator

James Cook University Hospital, Middlesbrough, United Kingdom; Recruiting
Dr. Nick Linker, Principal Investigator

Royal Bournemouth Hospital, Bournemouth, United Kingdom; Recruiting
Dr. Adrian Rozkovec, Principal Investigator

Leeds General Infirmary, Leeds, United Kingdom; Recruiting
Dr. Chris Pepper, Principal Investigator

Princess Royal Hospital, Orpington, Kent, United Kingdom; Recruiting
Dr. Steve Sutcliffe, Principal Investigator

St. Thomas' Hospital, London, United Kingdom; Recruiting
Dr. Aldo Rinaldi, Principal Investigator

University Hospital of Wales, Cardiff, United Kingdom; Recruiting
Dr. Zaheer Yousef, Principal Investigator

New Cross Hospital, Wolverhampton, United Kingdom; Recruiting
Dr. Rajpal Singh, Principal Investigator

Blackpool Victoria Hospital, Blackpool, United Kingdom; Recruiting
Dr. Graham Goode, Principal Investigator

Colchester General, Colchester, United Kingdom; Recruiting
Dr. Kare Tang, Principal Investigator

Norfolk and Norwich University Hospital, Norwich, United Kingdom; Recruiting
Dr. Ian Williams, Principal Investigator

The Prince Charles Hospital, Brisbane, Queensland, Australia; Recruiting
Steve Graves, Phone: 07 3139 4711
Russell Denman, Principal Investigator

Royal Brisbane & Womens' Hospital, Brisbane, Queensland, Australia; Recruiting
Leeanne Palethorpe, Phone: 07 3636 5281
Paul Martin, Principal Investigator

Princess Alexandra Hospital, Brisbane, Queensland, Australia; Recruiting
Cindy Hall, Phone: 07 3240 7676
Gerald Kaye, Principal Investigator

Royal Adelaide Hospital, Adelaide, South Australia, Australia; Recruiting
Vanessa Maxwell, Phone: 08 8222 5789
Glenn Young, Principal Investigator

Calvary Wakefield Hospital, Adelaide, South Australia, Australia; Recruiting
AnneMarie Mitchell, Phone: 08 82234288
Glenn Young, Principal Investigator

Flinders Medical Center, Adelaide, South Australia, Australia; Recruiting
Bel Vuljanic, Phone: 08 8404 2007
Andrew McGavigan, Principal Investigator

Additional Information

Starting date: May 2007
Ending date: April 2012
Last updated: April 23, 2009

Page last updated: October 19, 2009

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009